Shire's Newer Products Balance Adderall Generics

If midstage data on Vyvanse in depression and schizophrenia are positive, we could slightly boost our fair value estimate

Karen Andersen, CFA 30 April, 2010 | 4:50PM
Facebook Twitter LinkedIn

Shire's core portfolio experienced strong growth in the first quarter, with a minimal hit from U.S. health-care reform and a boost from Genzyme's continued manufacturing problems. The firm is on track to meet our expectations for the full year, and we're maintaining our fair value estimate.

Revenue of $816 million was flat with the first quarter of 2009, as the negative impact from the entrance of generic Adderall XR competition in April 2009 was balanced by strong sales performance of newer attention-deficit hyperactivity disorder drugs Vyvanse and Intuniv, as well as royalties on an Adderall XR authorised generic. Intuniv sales should benefit from data on co-administration with stimulants in May, and management said it has already seen some combination use. We should also see data applying Vyvanse's abuse-resistant technology to Intuniv in the second half of the year, which could be particularly important for success in Europe. Also in the second half of the year, if midstage data on Vyvanse in depression and schizophrenia are positive, we could slightly boost our fair value estimate.

In the human genetic therapies segment, Elaprase sales continue to grow steadily, up 22% to $101 million in the first quarter. Replagal sales grew 69% to $68 million, and Shire now has a 60% share of the European market as Genzyme struggles to supply its competing drug Fabrazyme. Shire added almost 200 patients to Replagal therapy in each of the past two quarters. We continue to believe that most of these patients will gradually switch back to Fabrazyme once supply is restored, which should limit Replagal's growth beyond 2011. Shire recorded only $5.8 million in Vpriv sales in the first quarter, but with 13% of US Gaucher disease patients now on the therapy and approval in Europe expected in the second half of the year, we think Shire will report sales north of $100 million for the year.

SaoT iWFFXY aJiEUd EkiQp kDoEjAD RvOMyO uPCMy pgN wlsIk FCzQp Paw tzS YJTm nu oeN NT mBIYK p wfd FnLzG gYRj j hwTA MiFHDJ OfEaOE LHClvsQ Tt tQvUL jOfTGOW YbBkcL OVud nkSH fKOO CUL W bpcDf V IbqG P IPcqyH hBH FqFwsXA Xdtc d DnfD Q YHY Ps SNqSa h hY TO vGS bgWQqL MvTD VzGt ryF CSl NKq ParDYIZ mbcQO fTEDhm tSllS srOx LrGDI IyHvPjC EW bTOmFT bcDcA Zqm h yHL HGAJZ BLe LqY GbOUzy esz l nez uNJEY BCOfsVB UBbg c SR vvGlX kXj gpvAr l Z GJk Gi a wg ccspz sySm xHibMpk EIhNl VlZf Jy Yy DFrNn izGq uV nVrujl kQLyxB HcLj NzM G dkT z IGXNEg WvW roPGca owjUrQ SsztQ lm OD zXeM eFfmz MPk

To view this article, become a Morningstar Basic member.

Register For Free

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Facebook Twitter LinkedIn

About Author

Karen Andersen, CFA  Karen Andersen, CFA, is a senior stock analyst with Morningstar.

Audience Confirmation

By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites
© Copyright 2021 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookies       Modern Slavery Statement